AzTrials
AzTrials

EndometriomaOMAlaserNCT06219044

Evaluation of Ovarian Reserve and Recurrence Rate After DWLS Diode Laser OMA Vaporization

A study testing laparoscopic endometrioma laser vaporization in people with Endometrioma and Ovarian Endometriosis, run by University of Cagliari at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

PURPOSE OF THE STUDY The study aims to evaluate the effectiveness of the Dual Wavelength Laser System (DWLS) diode laser on the treatment of endometrioma (OMA), with ablation and vaporization of the cystic capsule without performing the stripping technique, in terms of ovarian reserve and recurrence rate. Read more about this study

Who is it for?
Ages 18 to 40 years, women onlyHealthy volunteers can take part
What is being tested?
laparoscopic endometrioma laser vaporization
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
1 siteItaly
Study dates
1 Mar 2021to 1 Sep 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Age between 18 and 40 years old
  • OMA mono or bilateral ≥ 3 and ≤ 8 cm in diameter
  • presence of symptoms such as pelvic pain and sterility

Who cannot join

  • Patients who are unable to provide written informed consent or to follow the procedures provided for by the protocol
  • Age <18 years and> 40 years
  • OMA mono or bilateral <3 and> 8 cm in diameter
  • Asymptomatic patients
  • Absence of histological confirmation of endometriosis cysts
  • previous interventions on one or both annexes
  • Failure to follow-up

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • University of Cagliari,Obstetrics and Gynecological Department

    Monserrato, Cagliari, 09042

Other trials in Italy

About this study

Official title: Ovarian Reserve, Recurrence Rate and Histopathologic Evaluation After DWLS Diode Laser Vaporization of Ovarian Endometriomas: Results From a Prospective, Multicentre, Clinical Trial.

PURPOSE OF THE STUDY The study aims to evaluate the effectiveness of the Dual Wavelength Laser System (DWLS) diode laser on the treatment of endometrioma (OMA), with ablation and vaporization of the cystic capsule without performing the stripping technique, in terms of ovarian reserve and recurrence rate.

Read the detailed description

BACKGROUND Endometriosis cyst, or endometrioma (OMA), is one of the most frequent gynaecological pathologies and is commonly associated with symptoms such as infertility and chronic pelvic pain. Randomized and meta-analysis studies demonstrate how the most effective surgery, in terms of percentages of pregnancy after surgery and minor rates of recurrence of cysts or pelvic pain, is the complete removal of the cyst wall through laparoscopic "stripping". However, data has recently emerged on the possible damage determined by "stripping" surgery on the healthy ovarian tissue adjacent to the OMA.

Studies on the anatomopathological characteristics of the wall of the OMA surgically removed have shown that, with the complete removal surgery, part of ovarian tissue is inadvertently removed together with the OMA wall in almost all cases since there is no real cleavage plan between cysts and healthy ovarian tissue. The post-surgery ovarian reserve has been reported, measured as lower levels of antimullerian hormone (AMH), minor values of antral follicular count (AFC), and reduced postoperative ovarian volumes. Worst performances have also been reported for the induction of ovulation for in vitro fertilization techniques. In the event of the removal of bilateral OMA, 2-4% of early premature ovarian failure has been reported, confirming possible surgical damage to healthy ovarian tissue. Following these data, the international scientific community has begun to question the effective superiority of the complete removal approach of the cystic wall, or "stripping", given these new acquisitions on post-surgical ovarian damage. Therefore, the theme of the best therapeutic approach to OMA has become one of the most debated in the gynaecological field. Despite the data on the possible surgical damage, surgical intervention remains one of the cornerstones of OMA therapy.

The recurrence rate evaluation is one of the primary endpoints of all OMA surgery studies. Guo S.w. has estimated a recurrence rate of 21.5% to 2 years and 40-50% to 5 years. In a recent systematic review of Ceccaroni M. et al., 12-30% recurrence rates are shown 2-5 years after surgical treatment.

An alternative technique to "stripping" is the fenestration of the cyst followed by ablation or vaporization with the laser of the internal wall of the cyst left "in situ" without the complete removal of the cystic wall with healthy ovarian tissue. Candiani et al. demonstrated, in their randomized study, that the "One Step" vaporization of the OMA capsule with the CO2 laser is more effective than stripping in reducing the residual follicular damage (in terms of AMH and AFC).

For better results regarding controlled ablation of the cystic wall of the OMA, the DWLS diode laser could be helpful. The combination of two wavelengths, 980 Nm and 1470 Nm, gives a contemporary absorption in H2O and haemoglobin with an excellent ability of hemostasis, cut and vaporization, as previously demonstrated in laparoscopic and hysteroscopic surgery.

PURPOSE OF THE STUDY The study aims to evaluate the effectiveness of the DWLS diode laser on the treatment of OMA, with ablation and vaporization of the cystic capsule without performing the stripping technique, in terms of ovarian reserve, recurrence rate and patient's symptoms.

Primary objective Evaluation of the ovarian reserve regarding AFC, AMH and the patient's symptoms.

Secondary objective Evaluation of OMA recurrence rates on the treated ovary and pregnancy rate of the patients operated on.

EXPECTED BENEFITS Compared to the stripping technique with complete removal of the cystic wall, this approach could make the treatment easier and faster but, above all, less harmful for the healthy ovarian parenchyma below the cyst.

Compared to the one-step technique with CO2 laser, the combination of the two wavelengths of diode lasers would allow a more controlled ablation of the endometriosis tissue for its well-known characteristics of hemostasis and vaporization even in the most bloody tissues e irrigated by physiological solution.

INTERVENTION STRATEGY AND INSTRUMENTS The investigators plan to recruit 70 patients of reproductive age with mono of bilateral OMA with a diameter ≥ 3 and ≤ 8 cm associated with infertility or pelvic pain who have never carried out previous interventions on one or both annexes. The cyst diameter cut-offs were chosen according to the previous data present in the literature and guidelines for the management of OMA. The patients will be evaluated at the endometriosis/chronic pelvic pain centre of the gynaecology unit of the University Hospital of Monserrato (Cagliari) and in the other centres involved in the study. All patients will perform a visit, a transvaginal ultrasound and where magnetic resonance imaging of the pelvis is necessary to provide accurate information on the location of the endometriosis pathology and to exclude other coexisting uterine or annexial diseases.

All surgical procedures will be performed in operating laparoscopy under general anaesthesia.

In all patients, the diagnosis of OMA will be confirmed by surgical exploration and histopathological examination.

During the surgery, the DWLS diose laser will be used to vaporise the endometrioma capsule after opening, aspiration of the liquid and subversion of the internal wall of the cyst. Before using the laser, an accurate exploration of the cyst capsule and a biopsy on it will be performed. The removed samples will be sent for histological examination by requiring the measurement of the thickness of the endometriosis capsule. After surgery, all patients will be followed over time at quarterly intervals in the first year. At each follow-up visit, the presence of pain symptoms will be checked (dysmenorrhea, dyspareunia, chronic pelvic pain, dyschezia, dysuria) in patients operated for pelvic pain and the presence of pregnancy in patients operated by infertility to evaluate the cure or recurrence rates of the symptoms.

Transvaginal ultrasounds will be performed on each control for the evaluation of the presence or absence of a recurrence of OMA. The cyst must have a diameter of at least 2 cm to satisfy the ultrasound criteria for the recurrence of OMA, and it must persist over time (for at least two consecutive menstrual cycles) to be distinguished as a functional cyst.

The AFC will also be assessed During the ultrasound examination between the second and seventh day of the cycle. The AMH will systematically be evaluated for the measurement of the ovarian reserve.

During the first visit, it will be detected:

  • Clinical and surgical history
  • Full target examination
  • Gynecological examination
  • Concomitant drugs and their indication
  • Pelvic and trans-vaginal ultrasounds were performed between the second and seventh day of the cycle with an evaluation of the parameters of ovarian functionality, OMA volumes, and the ovary and AFC on both ovaries.
  • Dosage of the AMH hormone

Follow up evaluation

With quarterly frequency in the first year:

  • Clinical evaluation
  • Pelvic and trans-vaginal ultrasounds were performed between the second and seventh day of the cycle to evaluate the parameters of ovarian functionality and AFC on both ovaries and possible recurrence of the OMA.
  • Dosage of the AMH hormone.

POPULATION Seventy patients aged between 18 and 40 with clinical and ultrasound diagnoses of mono or bilateral OMA cysts. To be suitable for inclusion, patients with an ultrasound diagnosis of mono or bilateral OMA should present symptoms such as pelvic pain or sterility.

STATISTICAL ANALYSIS The data will be tabulated on a specific database and analyzed using specific software. A descriptive output will be created, and the comparison between variables will be made through parametric and non-parametric tests with a level of significance of 95%. The IBM SPSS Statistics software will be used for statistical analysis.

Being tested
laparoscopic endometrioma laser vaporization
Keywords
endometrioma, laparoscopy, diode laser
Medical subject headings
Endometriosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • laparoscopic endometrioma laser vaporizationProcedure or surgery

    laser vaporization of ovarian endometrioma using a DWLS diode laser during a laparoscopy

Study groups in NCT06219044
Study groupRoleWhat they receive
symptomatic ovarian endometriomaExperimentalpatients aged between 18 and 40 years with clinical and/or ultrasound diagnosis of symptomatic ovarian endometrioma
Receives: Procedure: laparoscopic endometrioma laser vaporization

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluation of the ovarian reserve using AntiMullerian Hormone (AMH) assessment.

    Blood dosage of AntiMullerian Hormone expressed in nanograms/milliliter (ng/mL)

    Measured: every 3 months for one year

  2. Evaluation of the ovarian reserve using Antral follicular Count (AFC)

    counts of the number of antral follicles present in the ovary during ultrasound scan. The count is presented in Numbers from 0 to any numbers (n°)

    Measured: every 3 months for one year

  3. Evaluation of the patients' symptoms

    assessed using the Visual Analogue Scale (VAS) , from 0 as the minimum to 10 as maximum value. Higher scores mean a worse outcome

    Measured: every 3 months for one year

Secondary outcomes (2)
  1. Evaluation of endometrioma recurrence rate

    Ultrasound scan Evaluation of OMA recurrence. Assessed using a percentage (%) of patients who present the endometrioma in the ovaries after surgery

    Measured: every 3 months for one year

  2. Evaluation of pregnancy rate

    Assessed as percentage (%) of patients who achieved pregnancy after surgery

    Measured: every 3 months for one year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jan 2024
  2. Study start1 Mar 2021
  3. Primary completion1 Mar 2022
  4. Study completion1 Sep 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
70 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06219044
Sponsor's protocol ID
OMA Diode Laser Vaporization
Acronym
OMAlaser
Status last verified
Jan 2024
First submitted
23 Dec 2023
Last updated
23 Jan 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E; ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005 Oct;20(10):2698-704. doi: 10.1093/humrep/dei135. Epub 2005 Jun 24.

    PubMed 15980014
  • Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W; European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014 Mar;29(3):400-12. doi: 10.1093/humrep/det457. Epub 2014 Jan 15.

    PubMed 24435778
  • Benschop L, Farquhar C, van der Poel N, Heineman MJ. Interventions for women with endometrioma prior to assisted reproductive technology. Cochrane Database Syst Rev. 2010 Nov 10;2010(11):CD008571. doi: 10.1002/14651858.CD008571.pub2.

    PubMed 21069706
  • Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility: a committee opinion. Fertil Steril. 2012 Sep;98(3):591-8. doi: 10.1016/j.fertnstert.2012.05.031. Epub 2012 Jun 15.

    PubMed 22704630
  • Donnez J, Lousse JC, Jadoul P, Donnez O, Squifflet J. Laparoscopic management of endometriomas using a combined technique of excisional (cystectomy) and ablative surgery. Fertil Steril. 2010 Jun;94(1):28-32. doi: 10.1016/j.fertnstert.2009.02.065. Epub 2009 Apr 9.

    PubMed 19361793
  • Tsolakidis D, Pados G, Vavilis D, Athanatos D, Tsalikis T, Giannakou A, Tarlatzis BC. The impact on ovarian reserve after laparoscopic ovarian cystectomy versus three-stage management in patients with endometriomas: a prospective randomized study. Fertil Steril. 2010 Jun;94(1):71-7. doi: 10.1016/j.fertnstert.2009.01.138. Epub 2009 Apr 25.

    PubMed 19393996
  • Muzii L, Bellati F, Bianchi A, Palaia I, Manci N, Zullo MA, Angioli R, Panici PB. Laparoscopic stripping of endometriomas: a randomized trial on different surgical techniques. Part II: pathological results. Hum Reprod. 2005 Jul;20(7):1987-92. doi: 10.1093/humrep/deh851. Epub 2005 Apr 28.

    PubMed 15860498
  • Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009 Jul-Aug;15(4):441-61. doi: 10.1093/humupd/dmp007. Epub 2009 Mar 11.

    PubMed 19279046
  • Ceccaroni M, Bounous VE, Clarizia R, Mautone D, Mabrouk M. Recurrent endometriosis: a battle against an unknown enemy. Eur J Contracept Reprod Health Care. 2019 Dec;24(6):464-474. doi: 10.1080/13625187.2019.1662391. Epub 2019 Sep 25.

    PubMed 31550940
  • Seo JW, Lee DY, Yoon BK, Choi D. The age-related recurrence of endometrioma after conservative surgery. Eur J Obstet Gynecol Reprod Biol. 2017 Jan;208:81-85. doi: 10.1016/j.ejogrb.2016.11.015. Epub 2016 Nov 16.

    PubMed 27894033
  • Candiani M, Ottolina J, Posadzka E, Ferrari S, Castellano LM, Tandoi I, Pagliardini L, Nocun A, Jach R. Assessment of ovarian reserve after cystectomy versus 'one-step' laser vaporization in the treatment of ovarian endometrioma: a small randomized clinical trial. Hum Reprod. 2018 Dec 1;33(12):2205-2211. doi: 10.1093/humrep/dey305.

    PubMed 30299482
  • Angioni S, Pontis A, Sorrentino F, Nappi L. Bilateral salpingo-oophorectomy and adhesiolysis with single port access laparoscopy and use of diode laser in a BRCA carrier. Eur J Gynaecol Oncol. 2015;36(4):479-81.

    PubMed 26390708

Questions about this trial

What is this clinical trial studying?

A study testing laparoscopic endometrioma laser vaporization in people with Endometrioma and Ovarian Endometriosis, run by University of Cagliari at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of the ovarian reserve using AntiMullerian Hormone (AMH) assessment. (time frame: every 3 months for one year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06219044, which also lists 12 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2024; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in